JP4691257B2 - シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法 - Google Patents

シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法 Download PDF

Info

Publication number
JP4691257B2
JP4691257B2 JP2000594486A JP2000594486A JP4691257B2 JP 4691257 B2 JP4691257 B2 JP 4691257B2 JP 2000594486 A JP2000594486 A JP 2000594486A JP 2000594486 A JP2000594486 A JP 2000594486A JP 4691257 B2 JP4691257 B2 JP 4691257B2
Authority
JP
Japan
Prior art keywords
cpn10
ifn
day
mice
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000594486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002535286A5 (OSRAM
JP2002535286A (ja
Inventor
モートン、ハレ
キャバナー、アリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of JP2002535286A publication Critical patent/JP2002535286A/ja
Publication of JP2002535286A5 publication Critical patent/JP2002535286A5/ja
Application granted granted Critical
Publication of JP4691257B2 publication Critical patent/JP4691257B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
JP2000594486A 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法 Expired - Fee Related JP4691257B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment
AU8239 1999-01-20
AUPP8239 1999-01-20
PCT/AU2000/000032 WO2000043033A1 (en) 1999-01-20 2000-01-20 CHAPERONIN 10 AND β-INTERFERON THERAPY OF MULTIPLE SCLEROSIS

Publications (3)

Publication Number Publication Date
JP2002535286A JP2002535286A (ja) 2002-10-22
JP2002535286A5 JP2002535286A5 (OSRAM) 2007-02-15
JP4691257B2 true JP4691257B2 (ja) 2011-06-01

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000594486A Expired - Fee Related JP4691257B2 (ja) 1999-01-20 2000-01-20 シャペロニン１０及びβ−インターフェロンによる多発性硬化症の治療方法

Country Status (12)

Country Link
US (1) US20090214473A1 (OSRAM)
EP (1) EP1150703B1 (OSRAM)
JP (1) JP4691257B2 (OSRAM)
KR (1) KR100694011B1 (OSRAM)
AT (1) ATE313332T1 (OSRAM)
AU (2) AUPP823999A0 (OSRAM)
CA (1) CA2361081C (OSRAM)
DE (1) DE60024967T2 (OSRAM)
DK (1) DK1150703T3 (OSRAM)
ES (1) ES2255484T3 (OSRAM)
PT (1) PT1150703E (OSRAM)
WO (1) WO2000043033A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
KR20080098579A (ko) 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
KR20080075505A (ko) * 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
DE60024967D1 (en) 2006-01-26
ATE313332T1 (de) 2006-01-15
EP1150703B1 (en) 2005-12-21
EP1150703A1 (en) 2001-11-07
DK1150703T3 (da) 2006-05-29
US20090214473A1 (en) 2009-08-27
EP1150703A4 (en) 2004-11-10
KR20020002376A (ko) 2002-01-09
DE60024967T2 (de) 2006-08-17
AU771867B2 (en) 2004-04-01
CA2361081C (en) 2010-09-21
AU2527100A (en) 2000-08-07
CA2361081A1 (en) 2000-07-27
AUPP823999A0 (en) 1999-02-11
JP2002535286A (ja) 2002-10-22
PT1150703E (pt) 2006-05-31
ES2255484T3 (es) 2006-07-01
WO2000043033A1 (en) 2000-07-27
KR100694011B1 (ko) 2007-03-12

Similar Documents

Publication Publication Date Title
US20090214473A1 (en) Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
US8454967B2 (en) Compositions and methods for modulating the immune system
US20210244789A1 (en) Compositions and methods for treatment of intracellular damage and bacterial infection
Takagi et al. Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice
EP0506785A1 (en) Improved treatment of autoimmune diseases by aerosol administration of auto antigens
JP4804626B2 (ja) 免疫レギュレータ
EP0744949A4 (en) TREATMENT AND / OR PREVENTION OF SUGAR DIABETES TYPE I BY ADMINISTRATION OF INTERFERON GAMMA
JP2007517808A (ja) Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
US20110294736A1 (en) Compounds and methods for the treatment of autoimmune and inflammatory disease
Di Rosa et al. Lack of Th2 cytokine increase during spontaneous remission of experimental allergic encephalomyelitis
KR100424212B1 (ko) 1형인터페론을포함하는자가-면역질환치료용조성물
Jung et al. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN
Aizman et al. The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice
NZ569604A (en) Treatment of HIV comprising administering a corticotropin releasing factor (CRF) peptide
JPH11510806A (ja) 免疫抑制治療のためのインターロイキン１０およびシクロスポリンの併用
KR20120064981A (ko) 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
Zaheer et al. Clinical course of myelin oligodendrocyte glycoprotein 35–55 induced experimental autoimmune encephalomyelitis is aggravated by glia maturation factor
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
WO2025151037A1 (en) Therapeutic methods and related compositions
AU2003273758A1 (en) Treatment of allergic conditions by use of il 21
Zhang Emerging therapeutic targets in multiple sclerosis: suppression and elimination of myelin-autoreactive T-lymphocytes
Batbayar et al. CAJMS F Ik W
TW201725047A (zh) 熱休克蛋白於治療異位性皮膚炎之用途
MXPA98001091A (en) Combined use of interleukin-10 and cyclosporine for immunosupres therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100930

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110221

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140225

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees